Global Tuberculosis Drugs Market, By Therapy Type (First Line Drugs Therapy, Second Line Drugs Therapy, Combination Drugs Therapy), and Geography - Insights, Opportunity Analysis, and Industry Forecast till 2024

Tuberculosis is a deadly infectious disease that affects the lungs. Among diseases, tuberculosis is the second largest cause of death worldwide. Tuberculosis are broadly classified as latent tuberculosis and active tuberculosis. Globally around 10% of latent infections develop into active tuberculosis. Infections that do not show any symptoms are called latent tuberculosis. In 2015, the malady resulted in 1.8 million deaths and 10.4 million new reported cases. In 2015, in the U.S., there were 9,557 tuberculosis cases reported. Based on the statistics of Center for Disease Control and Prevention, a 1.6% increase in the number of tuberculosis cases was observed in 2015 as compared to those reported in 2014. Though there is an increase in the number of tuberculosis cases, the incidence rate per 100,000 persons has been around 3.0 since 2013.

Get Exclusive Discount on this CMI Report: https://www.coherentmarketinsights.com/insight/request-discount/191

Market Dynamics

Asia and Africa are the largest markets for tuberculosis drugs, as these regions have the highest prevalence of TB. There are many initiatives taken to control the TB increasing cases. The United Nations’ Millennium Development Goals have framed various strategies to reduce TB prevalence and death rates by 2015, which can be achieved by WHO’s Stop TB Strategy. According World Health Organization, in 2006, 61% out of 2.5 million new smear positive cases with DOTS, and are all the new smear cases on the year, and the treatment was successful in 85% cases. The estimated global incidence rate of tuberculosis shown decline rate by 0.6% in 2005 and 2006. In 2006, the incidence rate of tuberculosis became stable in the Europe and is declining gradually in the other WHO countries. World Health Organization has an approximation that the occurrence of tuberculosis and death rates are declining faster than the incidence rate.

Download Exclusive PDF Brochure of This Report : https://www.coherentmarketinsights.com/insight/request-sample/191

Market Taxonomy

This report segments the global tuberculosis drugs market on the basis of therapy type and geography. On the basis of therapy type, the market is categorized into first line drugs, Second line drugs and combination drug therapy. Under First line drugs, the market is further segmented into drugs such as Isoninazid, Rifampicin, Ethambutol, Pryazinamide, and Strepromycin. The second line drugs are further segmented into Injectable, Fluoroquinolones, and Bacteriostatic Agents and Others. For comprehensive understanding of market dynamics, the global tuberculosis drugs market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Key features of the study:

This report provides in-depth analysis of the tuberculosis drugs market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2015 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

Browse Global Strategic Business Report : https://www.coherentmarketinsights.com/market-insight/tuberculosis-drugs-market-191

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global tuberculosis drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans

Key companies covered as a part of this study include Pfizer Inc, Lupin Laboratories Ltd, AstraZeneca Plc, Cadila Pharmaceuticals, Novartis AG, Alkem Laboratories Ltd, and Cipla Ltd.

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, end user upgrades, market expansion, and marketing tactics

The global tuberculosis drugs market report caters to various stakeholders in this industry, including investors, drug manufacturers, distributors and suppliers for tuberculosis drugs, research and consulting firms, new entrants, and financial analysts

Various strategy matrices used in analyzing the tuberculosis drugs market would provide stakeholders vital inputs to make strategic decisions accordingly

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.